Early switching strategies in antidepressant non-responders: current evidence and future research directions. (Q38211978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Early switching strategies in antidepressant non-responders: current evidence and future research directions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Raymond W. Lam

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2

Roger S McIntyre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

601-609

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40263-014-0171-5

18 March 2020

exact match

0 references

cites work

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Major depressive disorder treatment guidelines in America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early switch strategy in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Duration of antidepressant drug treatment. What is an adequate trial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Response rates to fluoxetine in subjects who initially show no improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

When should a trial of fluoxetine for major depression be declared failed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Onset, time course and trajectories of improvement with antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early switch strategy in patients with major depressive disorder: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Clinical effectiveness: the importance of psychosocial functioning outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Toward a neuroimaging treatment selection biomarker for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Guidance for the discontinuation or switching of antidepressant therapies in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0171-5

Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement.

21 January 2018

1 reference

12 December 2020

Early symptom change prediction of remission in depression treatment.

1 reference

12 December 2020

Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis.

1 reference

12 December 2020

Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review

1 reference

12 December 2020

Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction

1 reference

12 December 2020

Chronological milestones to guide drug change. When should clinicians switch antidepressants?

1 reference

12 December 2020

Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial

1 reference

12 December 2020

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.

1 reference

12 December 2020

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome

1 reference

12 December 2020

Timing of Onset of Antidepressant Response With Fluoxetine Treatment

1 reference

12 December 2020

A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression

1 reference

12 December 2020

10.1007/S40263-014-0171-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json

release_vi6qcchtxjfihcnhlgbwycblyi

18 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vi6qcchtxjfihcnhlgbwycblyi

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24831418%20AND%20SRC:MED&resulttype=core&format=json